Tempus provides an established, validated platform to reduce development time and cost associated with companion diagnostic approval.
Improve program success
As one of the leaders pioneering real-world data, Tempus’ robust clinico-genomics database can be used in tandem with trial sequencing data to set up control arms, compare trial data to real-world data, and generate clinically-meaningful comparator data throughout the trial. Tempus’ sequencing data covers DNA tumor/normal, RNA transcriptome, and key immunotherapy metrics, allowing for a more holistic view to stratify likely responders.
Companion diagnostic markers will be incorporated into assays already being used today by thousands of oncologists. Tempus provides a seamless commercialization and reimbursement strategy at launch.